Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Revolutionizing the Approach to Spine Surgery We are more than a medical technolo...
Revolutionizing the Approach to Spine Surgery ...
Since Mannatechâs establishment in 1994, the company has pioneered a commitment ...
Since Mannatechâs establishment in 1994, the ...
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...
Oncolytics is focused on obtaining regulatory a...
Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...
Heat Biologics a biopharmaceutical company that...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...
At Aethlon Medical, we are a leading developer ...
Join the National Investor Network and get the latest information with your interests in mind.